Literature DB >> 10027877

Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors.

L K Singh1, W Boucher, X Pang, R Letourneau, D Seretakis, M Green, T C Theoharides.   

Abstract

Urocortin (Ucn) is related to corticotropin-releasing hormone (CRH), and both are released in the brain under stress where they stimulate CRH 1 and 2 receptors (CRHR). Outside the brain, they may have proinflammatory actions through activation of mast cells, which are located perivascularly close to nerve endings and degranulate in response to acute psychological stress. Here, we report that a concentration of intradermal Ucn as low as 10 nM induced dose-dependent rat skin mast cell degranulation and increased vascular permeability. This effect appeared to be equipotent to that of calcitonin gene-related peptide and neurotensin. Ucn-induced skin vasodilation was inhibited by pretreatment with the mast cell stabilizer disodium cromoglycate (cromolyn) and was absent in the mast cell-deficient W/Wv mice. The selective nonpeptide CRH receptor 1 antagonist, antalarmin and the nonselective peptide antagonist astressin both reduced vascular permeability triggered by Ucn but not that by Substance P or histamine. In contrast, the peptide antagonist alpha-helical CRH-(9-41) reduced the effect of all three. The vasodilatory effect of Ucn was largely inhibited by pretreatment with H1 receptor antagonists, suggesting that histamine is the major mediator involved in vitro. Neuropeptide depletion of sensory neurons, treatment with the ganglionic blocker hexamethonium, or in situ skin infiltration with the local anesthetic lidocaine did not affect Ucn-induced vascular permeability, indicating that its in situ effect was not mediated through the peripheral nervous system. These results indicate that Ucn is one of the most potent triggers of rat mast cell degranulation and skin vascular permeability. This effect of Ucn may explain stress-induced disorders, such as atopic dermatitis or psoriasis, and may lead to new forms of treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027877

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

Review 1.  Mast cells and inflammation.

Authors:  Theoharis C Theoharides; Konstantinos-Dionysios Alysandratos; Asimenia Angelidou; Danae-Anastasia Delivanis; Nikolaos Sismanopoulos; Bodi Zhang; Shahrzad Asadi; Magdalini Vasiadi; Zuyi Weng; Alexandra Miniati; Dimitrios Kalogeromitros
Journal:  Biochim Biophys Acta       Date:  2010-12-23

2.  Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process.

Authors:  Jill Donelan; William Boucher; Nikoletta Papadopoulou; Michael Lytinas; Dean Papaliodis; Paul Dobner; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

Review 3.  Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications.

Authors:  M Larauche; C Kiank; Y Tache
Journal:  J Physiol Pharmacol       Date:  2009-12       Impact factor: 3.011

4.  Social isolation stress augments angiogenesis induced by colon 26-L5 carcinoma cells in mice.

Authors:  W Wu; J Murata; K Murakami; T Yamaura; K Hayashi; I Saiki
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor.

Authors:  Jeffrey S Stehouwer; Matthew S Birnbaum; Ronald J Voll; Michael J Owens; Susan J Plott; Chase H Bourke; Michael A Wassef; Clinton D Kilts; Mark M Goodman
Journal:  Bioorg Med Chem       Date:  2015-06-19       Impact factor: 3.641

6.  Pathogenic role of mast cells in the development of diabetic nephropathy: a study of patients at different stages of the disease.

Authors:  J M Zheng; G H Yao; Z Cheng; R Wang; Z H Liu
Journal:  Diabetologia       Date:  2011-12-01       Impact factor: 10.122

7.  Urocortin hyperpolarizes stomach smooth muscle via activation of Ca2+-sensitive K+ currents.

Authors:  P S Petkova-Kirova; H S Gagov; D B Duridanova
Journal:  J Muscle Res Cell Motil       Date:  2000       Impact factor: 2.698

Review 8.  Impact of mast cells in depression disorder: inhibitory effect of IL-37 (new frontiers).

Authors:  Pio Conti; Alessandro Caraffa; Gianpaolo Ronconi; Chiara M Conti; Spiros K Kritas; Filiberto Mastrangelo; Lucia Tettamanti; Theoharis C Theoharides
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

9.  Urocortin induced expression of COX-2 and ICAM-1 via corticotrophin-releasing factor type 2 receptor in rat aortic endothelial cells.

Authors:  Rongjian Zhang; Youhua Xu; Hong Fu; Juejin Wang; Lai Jin; Shengnan Li
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

10.  Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors.

Authors:  Youhua Xu; Rongjian Zhang; Jie Chen; Qichun Zhang; Juejin Wang; Jue Hu; Xiaowei Guan; Lai Jin; Hong Fu; Bo Gui; Yuanyuan Guo; Shengnan Li
Journal:  Br J Pharmacol       Date:  2009-06-30       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.